Rapid Commercialization Partners (RCP), a leader in the commercial acceleration of advanced biotechnology therapies, will be attending the NewYorkBIO Life Science Company Showcase - Aardvark Therapeutics to present; RCP announces expansion to their medical device team.
CAMBRIDGE, Mass. - Dec. 14, 2023 - RCP announed today they'll be attending NewYorkBIO's Life Science Company Showcase at the New York Stock Exchange as a sponsor and in support of client, Aadvark Therapeutics. Aardvark is a clinical-stage biopharmaceutical company focused on developing novel, small molecule therapeutics to activitate innate, homeostatic pathways for the treatment of metabolic diseases, inflammation, and other indications. Aardvark is looking at the interaction between the biology of the digestive tract and the brain that is mediated through the vagus nerve.
"We're delighted to be here as a sponsor and to support Chief Business Officer Bryan Jones and the remarkable team at Aardvark Therapeutics," Said Christina Ansted, Co-FOunder and CEO of Rapid Commercialization Partners. "The potential for development and commercialization of therapies emerging from their science - notably in indications like obesity and Prader-Willi Syndrome - are quite promising."
"We're also excited to announce the expansion of RCP's focus withint he medical device and technology sector," Added Ms. Ansted. "Terry Murray, a 35-year veteran of the medical device industry, is joining our executive team as Chief Strategy Officer, Medical Device & Technology. We're excited to expand our capabilities in MedTech and terry will be an integral part of that development."
"I'm thrilled to be joining such an exceptional team of experts and professionals here in Cambridge," commented Terry. "I started my sales career calling on MIT and Harvard BioLabs back in the late eighties. Having the privilege of joining the RCP team feels like I've come fully circle. Behing back in Harvard Square is like a homecoming."
Terry's decades of experience include senior executive positions with STERIS Corporation and SPX Corporation and more than twenty years of working to commercialize investor-driven startups in the medical device and life science fields. Terry also brings extensive experience from engineering and manfacturing firms dedicated to the design and development of medical technologies.
RCP was founded to bring a legacy of innovation to the commercialization of biotech products. Comprised of executive-level experts from critical functional areas within commercial biotechnology and medical device, we work as an integrated, but fractional extension of our client partners to build the commercial foundation, address observable inefficiency and bring needed therapies, technologies, and devices to patients faster and with improved fiscal responsibility.
RCP is headquartered in historic Harvard Square, in the heart of Cambridge, Massachusetts - a city world-renowned for its academic institutions and vibrant biotechnology community.
For more information, please contact timetovalue@rcpbio.com.
© 2023, Rapid Commercializatino Partners, Inc.